BioCardia, Inc. (BCDA): Price and Financial Metrics

BioCardia, Inc. (BCDA): $1.99

0.04 (-1.97%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

C

Add BCDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#183 of 332

in industry

BCDA Price/Volume Stats

Current price $1.99 52-week high $10.95
Prev. close $2.03 52-week low $1.84
Day low $1.97 Volume 47,300
Day high $2.18 Avg. volume 293,896
50-day MA $2.55 Dividend yield N/A
200-day MA $4.13 Market Cap 4.23M

BCDA Stock Price Chart Interactive Chart >


BioCardia, Inc. (BCDA) Company Bio


BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.


BCDA Latest News Stream


Event/Time News Detail
Loading, please wait...

BCDA Latest Social Stream


Loading social stream, please wait...

View Full BCDA Social Stream

BCDA Price Returns

1-mo -23.46%
3-mo -20.08%
6-mo -61.66%
1-year -79.54%
3-year -93.80%
5-year -96.31%
YTD -80.03%
2023 -68.22%
2022 7.73%
2021 -43.93%
2020 -5.98%
2019 -65.93%

Continue Researching BCDA

Here are a few links from around the web to help you further your research on BioCardia Inc's stock as an investment opportunity:

BioCardia Inc (BCDA) Stock Price | Nasdaq
BioCardia Inc (BCDA) Stock Quote, History and News - Yahoo Finance
BioCardia Inc (BCDA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!